INTERNATIONAL PATENT: REGENERON PHARMACEUTICALS, INC. FILES APPLICATION FOR "METHODS OF TREATING RECURRENT OVARIAN CANCER AND ENDOMETRIAL CANCER WITH BISPECIFIC ANTI-MUC16 X ANTI-CD28 ANTIBODIES IN COMBINATION WITH ANTI-PD-1 ANTIBODIES OR BISPECIFIC ANTI-MUC16 X ANTI-CD3 ANTIBODIES"

GENEVA, June 12 -- REGENERON PHARMACEUTICALS, INC. (777 Old Saw Mill River RoadTarrytown, New York 10591) filed a patent application (PCT/US2024/057927) for "METHODS OF TREATING RECURRENT OVARIAN CANCER AND ENDOMETRIAL CANCER WITH BISPECIFIC ANTI-MUC16 X ANTI-CD28 ANTIBODIES IN COMBINATION WITH ANTI-PD-1 ANTIBODIES OR BISPECIFIC ANTI-MUC16 X ANTI-CD3 ANTIBODIES" on Nov 28, 2024. With publication no. WO/2025/117869, the details related to the patent application was published on Jun 05, 2025.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Inventor(s): ULDRICK JR., Thomas Smith (c/o Regeneron Pharmaceuticals, In...